secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-115554
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio winds down operations, cuts 95% of staff, and explores sale or merger
-----------------------------------------------------------------------------

- Board approved wind-down of clinical and manufacturing operations; workforce reduced by 147 employees (~95%).
- Total wind-down cost estimated at $19.3M including $10.9M in severance and $4.4M asset write-down.
- CFO Han Choi and CSO Tirtha Chakraborty terminated without cause effective May 16, 2025; severance of ten months salary.
- Company exploring strategic alternatives including asset sale, licensing, merger, or sale of the company.
- Cash, cash equivalents and marketable securities were $91.9M as of Dec 31, 2024; Q1 results due May 14.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/0001193125-25-115554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525115554/d924194d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-115554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer